The number of shares in issue is 22,091,192.
|Shareholder||No. of ordinary shares||% of issued share capital|
|Crescent Capital II LP||2,652,325||12.01|
|Viridian Growth Fund LP||1,831,500||8.29|
|Hargreave Hale Limited||1,402,439||6.35|
|Amati Global Investors Limited||1,341,463||6.07|
|Livingbridge VC LLP||1,219,512||5.52|
|Octopus Investments Limited||1,219,512||5.52|
|Unicorn AIM VCT plc||1,219,512||5.52|
|Invest Northern Ireland||974,450||4.41|
|Crescent Capital III LP||731,707||3.31|
|Director||No. of ordinary shares||% of issued share capital|
|Dr Paul Gerard Kerr 1||532,500||2.41|
|Dr Richard John Buick||512,125||2.32|
|Dr Simon Gordon Douglas||255,800||1.16|
|Dr Alan Mawson 2||30,488||0.14|
|Timothy William Watts||12,195||0.06|
|Sonya Maria Ferguson||-||-|
|Colin James Walsh 3||-||-|
|James Alexander Fair||-||-|
(1) 21,250 of these Ordinary Shares are registered in the name of Paul Kerr's wife, Brigid Kerr.
(2) Alan Mawson is a non-executive director of Clarendon Fund Managers Limited ("Clarendon") and sits on Clarendon's investment committee. Clarendon is the fund manager for Nitech Growth Fund LP which holds 358,850 Ordinary Shares and Viridian Growth Fund LP.
(3) Colin Walsh is the Chief Executive and founder of Crescent Capital NI Limited, which is the fund manager for Crescent Capital II LP and Crescent Capital III LP.
Insofar as it is aware, 45.5% of the Company's securities is not in public hands.
The rights of shareholders are governed by UK law.
There are no restrictions on the transfer of the Company's ordinary shares.
The Company is subject to the provisions of the City Code on Takeover and Mergers.
Fusion Antibodies has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.
|28 August 2018||Chairman's Letter (inc. Notice of AGM to be held on 21 September 2018)|
Page last updated: 28 August 2018